PACB Long Call Strategy

PACB (Pacific Biosciences of California, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation.

PACB (Pacific Biosciences of California, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $394.5M, a beta of 2.40 versus the broader market, a 52-week range of 0.85-2.73, average daily share volume of 6.1M, a public-listing history dating back to 2010, approximately 575 full-time employees. These structural characteristics shape how PACB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.40 indicates PACB has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on PACB?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current PACB snapshot

As of May 15, 2026, spot at $1.13, ATM IV 79.40%, IV rank 15.06%, expected move 22.76%. The long call on PACB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on PACB specifically: PACB IV at 79.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a PACB long call, with a market-implied 1-standard-deviation move of approximately 22.76% (roughly $0.26 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PACB expiries trade a higher absolute premium for lower per-day decay. Position sizing on PACB should anchor to the underlying notional of $1.13 per share and to the trader's directional view on PACB stock.

PACB long call setup

The PACB long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PACB near $1.13, the first option leg uses a $1.13 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PACB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PACB shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$1.13N/A

PACB long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

PACB long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on PACB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on PACB

Long calls on PACB express a bullish thesis with defined risk; traders use them ahead of PACB catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

PACB thesis for this long call

The market-implied 1-standard-deviation range for PACB extends from approximately $0.87 on the downside to $1.39 on the upside. A PACB long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current PACB IV rank near 15.06% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PACB at 79.40%. As a Healthcare name, PACB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PACB-specific events.

PACB long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PACB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PACB alongside the broader basket even when PACB-specific fundamentals are unchanged. Long-premium structures like a long call on PACB are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current PACB chain quotes before placing a trade.

Frequently asked questions

What is a long call on PACB?
A long call on PACB is the long call strategy applied to PACB (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With PACB stock trading near $1.13, the strikes shown on this page are snapped to the nearest listed PACB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are PACB long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the PACB long call priced from the end-of-day chain at a 30-day expiry (ATM IV 79.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a PACB long call?
The breakeven for the PACB long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PACB market-implied 1-standard-deviation expected move is approximately 22.76%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on PACB?
Long calls on PACB express a bullish thesis with defined risk; traders use them ahead of PACB catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current PACB implied volatility affect this long call?
PACB ATM IV is at 79.40% with IV rank near 15.06%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related PACB analysis